Supply Chain Intelligence

Monopar Therapeutics Inc. Supply Chain

MNPR supply chain intelligence for Monopar Therapeutics Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

MNPR ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

21Suppliers
6Customers
1Debt Items
20Related Chains

Source-Backed Evidence Depth

Monopar Therapeutics Inc. (MNPR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

29Total relationships
3Distinct source URLs
7High confidence
0.737Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Monopar Therapeutics Inc. Suppliers

TickerNameConfidenceEvidence
ALEXION-PHARMACEUTICALS-INC ALEXION-PHARMACEUTICALS-INC 92% Alexion granted Monopar an exclusive worldwide license for the development and commercialization of ALXN1840
ALEXION ALEXION 90% We have also given Alexion the right of first negotiation regarding any rights should we intend to sublicense ALXN1840.
NORTHSTAR-MEDICAL-RADIOISOTOPES-LLC NORTHSTAR-MEDICAL-RADIOISOTOPES-LLC 90% NorthStar will provide Monopar with the therapeutic radioisotope actinium-225
XOMA XOMA Royalty Corporation 80% Reciprocal relationship from XOMA graph: Reciprocal relationship from MNPR graph: Reciprocal relationship from XOMA graph: Reciprocal relationship from MNPR graph: We also rely on certain rights to M…
XOMA XOMA Royalty Corporation 80% We also rely on certain rights to MNPR-101 that we have secured through a non-exclusive license agreement with XOMA.
ATNM Actinium Pharmaceuticals, Inc. 72% ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities for the production or testing of ALXN1840…
ATNM Actinium Pharmaceuticals, Inc. 72% Reciprocal relationship from ATNM graph: Reciprocal relationship from MNPR graph: Reciprocal relationship from ATNM graph: Reciprocal relationship from MNPR graph: Reciprocal relationship from ATNM g…
BHC Bausch Health Companies Inc. 72% Reciprocal relationship from BHC graph: Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently …
BHC Bausch Health Companies Inc. 72% ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities for the production or testing of ALXN1840…
ETON Eton Pharmaceuticals, Inc. 72% Reciprocal relationship from ETON graph: Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently…
ETON Eton Pharmaceuticals, Inc. 72% ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities for the production or testing of ALXN1840…
JNJ Johnson & Johnson 72% ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities for the production or testing of ALXN1840…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently …
LLY Eli Lilly and Company 72% Reciprocal relationship from LLY graph: Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently …
LLY Eli Lilly and Company 72% ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities for the production or testing of ALXN1840…
LNTH Lantheus Holdings, Inc. 72% ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities for the production or testing of ALXN1840…
LNTH Lantheus Holdings, Inc. 72% Reciprocal relationship from LNTH graph: Reciprocal relationship from MNPR graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical comp…
RARE Ultragenyx Pharmaceutical Inc. 72% ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities for the production or testing of ALXN1840…
RARE Ultragenyx Pharmaceutical Inc. 72% Reciprocal relationship from RARE graph: Reciprocal relationship from MNPR graph: Reciprocal relationship from RARE graph: Reciprocal relationship from MNPR graph: Reciprocal relationship from RARE g…
TLX Telix Pharmaceuticals Limited 72% Reciprocal relationship from TLX graph: Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently …
TLX Telix Pharmaceuticals Limited 72% ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities for the production or testing of ALXN1840…

Monopar Therapeutics Inc. Customers

TickerNameConfidenceEvidence
ALEXION-NORTHSTAR-MEDICAL-RADIOISOTOPES-LLC ALEXION-NORTHSTAR-MEDICAL-RADIOISOTOPES-LLC 62% e year ended December 31, 2024 , was primarily related to the payment of $3 million in 2025 related to the in-licensing of ALXN1840. Cash Flow Used in Investing Activities The increase to cash flow u…
DOTA-XOMA-LTD DOTA-XOMA-LTD 62% e year ended December 31, 2024 , was primarily related to the payment of $3 million in 2025 related to the in-licensing of ALXN1840. Cash Flow Used in Investing Activities The increase to cash flow u…
MONOPAR-THERAPEUTICS-AUSTRALIA-PTY-LTD MONOPAR-THERAPEUTICS-AUSTRALIA-PTY-LTD 62% how reporting companies must disclose going concern uncertainties in their financial statements. ASC 205 - 40 requires management to perform interim and annual assessments of an entity’s ability to c…
RESTATED-MONOPAR-THERAPEUTICS-INC RESTATED-MONOPAR-THERAPEUTICS-INC 62% any, could be implemented and the extent to which they will impact our financial condition and our business. Foreign currency exchange rates may adversely affect our consolidated financial statements…
XOMA XOMA Royalty Corporation 62% Reciprocal relationship from XOMA graph: Reciprocal relationship from MNPR graph: Reciprocal relationship from XOMA graph: Reciprocal relationship from MNPR graph: Reciprocal relationship from XOMA g…
XOMA-LTD XOMA-LTD 62% e year ended December 31, 2024 , was primarily related to the payment of $3 million in 2025 related to the in-licensing of ALXN1840. Cash Flow Used in Investing Activities The increase to cash flow u…

Monopar Therapeutics Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
MNPR-DEBT Debt stack $230,425 90% Market cache reports total debt of $230,425.

Monopar Therapeutics Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Monopar Therapeutics Inc..

Monopar Therapeutics Inc. Ownership

HolderNameConfidenceEvidence
MNPR-OWNER-JANUS-HENDERSON-GROUP-PLC JANUS HENDERSON GROUP PLC 90% 13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 82 tracked holders.

Monopar Therapeutics Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
TLX Telix Pharmaceuticals Limited 100.00 1 ['supplier']
LLY Eli Lilly and Company 100.00 1 ['supplier']
JNJ Johnson & Johnson 100.00 1 ['supplier']
XOMA XOMA Royalty Corporation 100.00 1 ['customer', 'supplier']
ATNM Actinium Pharmaceuticals, Inc. 100.00 1 ['supplier']
BHC Bausch Health Companies Inc. 100.00 1 ['supplier']
ETON Eton Pharmaceuticals, Inc. 100.00 1 ['supplier']
RARE Ultragenyx Pharmaceutical Inc. 100.00 1 ['supplier']
LNTH Lantheus Holdings, Inc. 100.00 1 ['supplier']
ANIK Anika Therapeutics, Inc. 50.00 2
AVBP ArriVent BioPharma, Inc. 50.00 2
AORT Artivion, Inc. 50.00 2
CYTOF Altamira Therapeutics Ltd. 50.00 2
BIOA BioAge Labs, Inc. 50.00 2
CVRX CVRx, Inc. 50.00 2
BSX Boston Scientific Corporation 50.00 2
DARE Daré Bioscience, Inc. 50.00 2
DSGN Design Therapeutics, Inc. 50.00 2
AXSM Axsome Therapeutics, Inc. 50.00 2
BTAI BioXcel Therapeutics, Inc. 50.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Monopar Therapeutics Inc..

Unlock full MNPR data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
MNPR
Unlock MNPR Supply Chain Data
Verified relationships include:
ALEXION-PHARMACEUTICALS-INCALEXION-PHARMACEUTICALS-INCSupplier92%
ALEXIONALEXIONSupplier90%
ALEXION-NORTHSTAR-MEDICAL-RADIOISOTOPES-LLCALEXION-NORTHSTAR-MEDICAL…Customer62%
DOTA-XOMA-LTDDOTA-XOMA-LTDCustomer62%
+25 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →